Amidst the intricate tapestry of pancreatic cancer’s heterogeneity, a quartet of recurrent gene mutations has unfailingly assumed the spotlight, with KRAS, TP53, SMAD4, and CDKN2A standing as the four cardinal genes predominantly implicated [3, 6, 9]. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.